Key Points Summary
Kangfang Biotech’s PD-1/VEGF dual antibody drug, Yivoxi, outperformed the current gold standard therapy in the phase III clinical trial for first-line treatment of advanced biliary tract cancer (AstraZeneca’s durvalumab combined with chemotherapy). Not only was the overall survival of patients significantly extended, but the time to tumor progression and the proportion of tumor shrinkage were also superior. This marks Yivoxi’s first major breakthrough in gastrointestinal tumors, following its success against Merck’s Keytruda in the lung cancer field. As the world’s first commercially available PD-1/VEGF dual antibody, Yivoxi has already been approved for lung cancer in China and is applying for approval in the United States, with the potential to change the landscape of immunotherapy for cancer.
Detailed Analysis
1. How was this “cancer battle” won? – How significant are the results?
This trial was a fair head-to-head comparison: patients with advanced biliary tract cancer were randomly divided into two groups, one receiving Yivoxi + chemotherapy, and the other receiving durvalumab (the current best treatment option) + chemotherapy. Neither the doctors nor the patients knew which group they were in (double-blind design).
- Key victory indicator: Overall Survival (OS): This measures the time from the start of treatment until death, which is the most critical indicator in cancer treatment. Patients in the Yivoxi group lived longer, and the difference was statistically significant (not incidental).
- Additional advantages: Progress-free Survival (PFS) + Response Rate (ORR): PFS refers to the time without tumor growth, and ORR refers to the proportion of patients whose tumors shrank. Both indicators were better in the Yivoxi group, indicating that patients not only lived longer but also had a better quality of life (slower tumor progression and more significant tumor shrinkage).
In short, Yivoxi outperformed the current gold standard in both “prolonging life” and “controlling tumors.”
2. Why is the defeat of durvalumab such big news? – How strong is the competitor?
Durvalumab is AstraZeneca’s leading PD-L1 antibody and is recommended as the best first-line treatment option in biliary tract cancer guidelines both domestically and internationally (it’s the industry benchmark). It is also the global sales leader for PD-L1 drugs, with sales exceeding $6 billion in 2025, a year-on-year increase of nearly 30%. Defeating such a strong competitor demonstrates the efficacy of Yivoxi.
More importantly, this is the first time a drug has surpassed the PD-L1 + chemotherapy gold standard in a phase III trial for biliary tract cancer, providing patients with a better treatment option (previously, they had no choice but durvalumab).
3. What makes Yivoxi such a “miraculous” drug? – What makes dual antibodies stronger than single antibodies?
Conventional PD-1/PD-L1 antibodies target a single point on the tumor cell. Yivoxi, on the other hand, is a PD-1/VEGF dual antibody, meaning it targets two points simultaneously:
- It activates the immune system to help it recognize and attack the tumor.
- It blocks the tumor’s blood supply, cutting off its nutrient supply (tumors need blood vessels to grow).
This dual approach is more effective than single-target antibodies. Yivoxi has already proven its strength in the lung cancer field, where it defeated the world’s best-selling PD-1 antibody, Merck’s Pembrolizumab. This latest victory further confirms the potential of dual antibodies.
4. What does this mean for Kangfang Biotech and the industry? – What is the impact?
- For Kangfang Biotech: Yivoxi’s scope of indications has expanded from lung cancer to gastrointestinal tumors (biliary tract cancer), opening up larger market opportunities. It is already available in China and is applying for approval in the US. If approved by the FDA, it could enter the global market and compete directly with Keytruda and durvalumab, potentially leading to significant increases in the company’s revenue and valuation.
- For the industry: Although PD-L1 antibodies are the foundation of immunotherapy, many patients develop resistance or do not respond well to them. The success of Yivoxi makes dual antibodies a promising new option, prompting pharmaceutical companies to invest more in this area. The competitive landscape may shift from a monopoly of single antibodies to a rise in dual antibodies.
5. What are the next developments to watch?
- US approval progress: The outcome of Yivoxi’s US approval application will determine whether dual antibodies can truly challenge the dominance of PD-L1 antibodies. If approved, doctors and patients worldwide will be more likely to use them, potentially leading to a surge in global sales.
- Further indication expansion: Will Yivoxi be tested in other gastrointestinal tumors (such as gastric and colorectal cancer) or solid tumors (such as liver and breast cancer)? If it proves effective in these conditions, its market will expand further.
- Industry competition: How are other companies progressing with dual antibody research? Will more competitive dual antibodies emerge? This will influence the overall direction of immunotherapy development.
In summary, Yivoxi’s success brings hope to patients with biliary tract cancer and positions dual antibodies as the new leaders in cancer treatment. In the coming years, the focus of immunotherapy may shift from single antibodies to dual antibodies, with Kangfang Biotech at the forefront of this trend.